仑伐替尼联合局部疗法治疗PD-L1基因阳性门脉癌栓程氏分型Ⅰ~Ⅲ型肝癌疗效观察

陈珑; 刘宇杰; 田素青; 王翠英; 何冬雷

doi:10.3971/j.issn.1000-8578.2022.21.0794

仑伐替尼联合局部疗法治疗PD-L1基因阳性门脉癌栓程氏分型Ⅰ~Ⅲ型肝癌疗效观察

Curative Effect of Lenvatinib Combined with Locoregional Therapy on PD-L1-positive Hepatocellular Carcinoma Patients with Type Ⅰ-Ⅲ Portal Vein Tumor Thrombus According to Cheng's Classification

摘要

摘要:
目的比较仑伐替尼联合局部疗法与局部疗法治疗PD-L1基因阳性门脉癌栓程氏分型Ⅰ~Ⅲ型肝癌患者的临床疗效。
方法仑伐替尼联合局部疗法组患者口服仑伐替尼12 mg每天一次（体重≥60 kg）或8 mg每天一次（体重 < 60 kg）。局部治疗组患者仅行局部治疗。回顾性分析两组患者临床资料和预后。
结果联合组和局部治疗组CR+PR分别为78.1%和53.6%。联合组有效率和疾病控制率均高于局部疗法组（P < 0.05）；生存分析结果提示：联合组患者的总生存率高于局部疗法组，差异有统计学意义（P < 0.05）。
结论仑伐替尼联合局部疗法治疗PD-L1基因阳性门脉癌栓程氏分型Ⅰ~Ⅲ型肝癌疗效较好，患者总生存率较局部疗法高。

Abstract:
Objective To compare curative effect between lenvatinib combined with locoregional therapy and locoregional therapy on PD-L1-positive hepatocellular carcinoma patients with type Ⅰ-Ⅲ portal vein tumor thrombus according to Cheng's classification.
Methods The patients in lenvatinib combined with locoregional therapy group received orally-administered lenvatinib at a dose of 12 mg qd for patients≥60 kg or 8 mg qd for patients < 60 kg. The locoregional therapy group only received locoregional therapy. We retrospectively analyzed the clinical data and prognosis of two groups.
Results The CR+PR were 78.1% and 53.6% in the combination group and locoregional therapy group, respectively (P < 0.05). The response rate, disease control rate and overall survival of the combination group were higher than those in the locoregional therapy group (P < 0.05).
Conclusion The curative effect and overall survival of lenvatinib combined with locoregional therapy is better than locoregional therapy on PD-L1-positive hepatocellular carcinoma patients with type Ⅰ-Ⅲ portal vein tumor thrombus according to Cheng's classification.

HTML全文

参考文献(15)

施引文献

资源附件(0)